Pharmaceuticals

Inflammatory Bowel Disease Treatment Market to Reach $39.39 Billion by 2029, Growing at a CAGR of 9.7%

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Inflammatory Bowel Disease Treatment Industry In 2025?

The inflammatory bowel disease treatment market has experienced robust expansion in recent years. This market is projected to grow from $25.26 billion in 2024 to $27.19 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.6%. The historical surge in this market can be attributed to the rising prevalence of inflammatory bowel disease, an escalating demand for biologics and immunomodulators, advancements in treatment options, an increasing geriatric population, and heightened awareness regarding the disease.

The inflammatory bowel disease treatment market size is projected to experience substantial growth over the coming years. Its value is anticipated to reach $39.39 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.7%. This expansion during the forecast period is primarily driven by factors such as increased investment in research and development activities, a rising demand for biosimilars, the growing incidence of inflammatory bowel disease in emerging markets, the expanding need for personalized medicine, and the integration of precision medicine into IBD treatment. Key trends expected in this period encompass an increasing number of product launches and approvals, the implementation of personalized dosing and treatment plans in IBD management, the utilization of telemedicine for remote monitoring of IBD patients, the ongoing exploration of microbiome-based therapies for IBD, and the wider adoption of value-based care models in IBD treatment.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Inflammatory Bowel Disease Treatment Industry?

The increasing occurrence of Crohn’s disease and ulcerative colitis is a major factor propelling the inflammatory bowel disease treatment market. These conditions, Crohn’s disease and ulcerative colitis, fall under the category of inflammatory bowel diseases (IBD), characterized by inflammation and the formation of ulcers (sores) within the digestive system. The growing number of individuals with Crohn’s disease and ulcerative colitis is anticipated to fuel the need for inflammatory bowel disease treatments, given their extensive use in alleviating bowel inflammation and minimizing or averting health complications. For example, data from March 2022 research, published by the United States National Library of Medicine, a US-based medical library, indicates that approximately 1.6 million Americans are currently affected by inflammatory bowel disease (encompassing Crohn’s disease or ulcerative colitis), with roughly 70,000 new IBD cases identified annually in the USA. Consequently, the expanding prevalence of Crohn’s disease and ulcerative colitis is poised to stimulate expansion in the inflammatory bowel disease treatment market.

How Is The Inflammatory Bowel Disease Treatment Market Classified Into Different Segments?

The inflammatory bowel disease treatment market covered in this report is segmented –

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes

2) By Type: Crohn’s Disease, Ulcerative Colitis

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide

2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol

4) By IL Inhibitors: Ustekinumab, Guselkumab

5) By Anti-Integrin: Vedolizumab, Natalizumab

6) By JAK Inhibitors: Tofacitinib, Filgotinib

7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

Which Competitive Trends Are Defining The Inflammatory Bowel Disease Treatment Market Structure?

Technological advancement stands out as a significant trend growing in popularity within the inflammatory bowel disease treatment market. Major companies operating in the inflammatory bowel disease treatment market are focusing on AI-driven registries to achieve a competitive edge. For example, in May 2024, Verantos, a real-world evidence (RWE) company based in California, launched the Inflammatory Bowel Disease Pragmatic Registry. This registry utilizes advanced artificial intelligence to generate high-quality real-world evidence (RWE) for ulcerative colitis and Crohn’s disease. The registry’s purpose is to facilitate the development of effective therapies by offering a comprehensive dataset with over 3 billion data points on patient care. It enables biopharma researchers to obtain detailed insights into disease severity, treatment effectiveness, and clinical outcomes by employing both structured and unstructured data from electronic health records.

Who Are The Prominent Global Companies Shaping The Inflammatory Bowel Disease Treatment Market?

Major companies operating in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Advanced Gastroenterology and Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly and Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic – Gastroenterology West P. C., Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

How Do Regional Market Performances Compare Within The Inflammatory Bowel Disease Treatment Industry?

North America was the largest region in the inflammatory bowel disease treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Inflammatory Bowel Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=6704&type=smp

Browse Through More Reports Similar to the Global Inflammatory Bowel Disease Treatment Market 2025, By The Business Research Company

Digestive Enzyme Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/digestive-enzyme-global-market-report

Smart Pills Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/smart-pills-global-market-report

Microbiomes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/microbiomes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795